NasdaqCM - Delayed Quote USD

NeuroSense Therapeutics Ltd. (NRSN)

1.9900 -0.1400 (-6.57%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

PR Newswire 2d ago

NRSN
-6.57%
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

PR Newswire 12d ago

NRSN
-6.57%
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

PR Newswire 18d ago

NRSN
-6.57%
^IXIC
NeuroSense Provides Update on Nasdaq Listing Compliance

PR Newswire 29d ago

NRSN
-6.57%
^IXIC
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

PR Newswire 1mo ago

NRSN
-6.57%
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

PR Newswire 1mo ago

NRSN
-6.57%
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

PR Newswire 1mo ago

NRSN
-6.57%
NeuroSense Issues CEO Letter to Shareholders

PR Newswire 2mo ago

NRSN
-6.57%
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

PR Newswire 2mo ago

NRSN
-6.57%
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

PR Newswire 3mo ago

NRSN
-6.57%
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

PR Newswire 3mo ago

NRSN
-6.57%
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

PR Newswire 4mo ago

NRSN
-6.57%

Performance Overview

Return	NRSN	S&P 500 (^GSPC)
YTD	-87.06%	+10.73%
1-Year	-90.39%	+11.11%
3-Year	-77.54%	+81.91%

U.S. markets closed

NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS